Triad Isotopes Competitors and Similar CompaniesClear all

Curium's competitors and similar companies include Prometheus Biosciences and MorphoSys.
Curium
Curium
Curium BidCo is a company that develops, manufactures, and distributes radiopharmaceutical products.
Prometheus Biosciences
Prometheus Biosciences
Prometheus Biosciences (formerly known as Precision IBD) is a biopharmaceutical company committed to the discovery, development, and commercialization of therapeutics and diagnostics for patients with gastroenterology and autoimmune diseases.
MorphoSys
MorphoSys
MorphoSys is a biotechnology company focused on the research and development of fully human antibodies.
Founding Date
Founding Date
2017
Founding Date
1995
Founding Date
1992
Type
Type
Subsidiary
Type
Subsidiary
Type
Subsidiary
Tags
Locations
Locations
Paris, FR HQ
Hausmannstätten, AT
Klagenfurt Am Wörthersee, AT
Linz, AT
Mechelen, BE
Laval, CA
Beijing, CN
see more
Locations
San Diego, US HQ
Locations
Planegg, DE HQ
Boston, US
Employees
Employees
2,300
Employees
9735% increase
Employees
464

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$6.8m (FY, 2022)
Revenue (est.)
€238.3m (FY, 2023)
Cost of goods
Cost of goods
€4.7m (FY, 2021)
Cost of goods
N/A
Cost of goods
€34.6m (FY, 2023)
Gross profit
Gross profit
(€4.7m) (FY, 2021)
Gross profit
N/A
Gross profit
€205.5m (FY, 2023)
Net income
Net income
(€34.3m) (FY, 2021)
Net income
($141.8m) (FY, 2022)
Net income
(€189.7m) (FY, 2023)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
$ 130m
Total funding raised
$ 126m
For sources of this data, please see the company profile

View Company Profiles

Prometheus Biosciences
HQ
San Diego, US

Prometheus Biosciences (formerly known as Precision IBD) is a biopharmaceutical company committed to the discovery, development, and commercialization of therapeutics and diagnostics for patients with gastroenterology and autoimmune diseases.

View company
MorphoSys
HQ
Planegg, DE

MorphoSys is a biotechnology company focused on the research and development of fully human antibodies.

View company